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Abstract
Objectives: To describe cervical cancer screening participation among women who have sex exclusively with women
(WSEW) and women who have sex with women and men (WSWM) compared with women who have sex exclusively with
men (WSEM), and women who have never had sex and compare this with bowel (colorectal) and breast screening participation.
To explore whether there is evidence of differential stage 3 cervical intraepithelial neoplasia (CIN3) or cervical cancer risk.
Methods: We describe cervical, bowel and breast cancer screening uptake in age groups eligible for the national screening
programmes, prevalent CIN3 and cervical cancer at baseline, and incident CIN3 and cervical cancer at five years follow-up,
among 218,674 women in UK Biobank, a cohort of healthy volunteers from the UK.
Results: Compared with WSEM, in adjusted analysis [odds ratio (95% confidence interval)], WSEW 0.10 (0.08–0.13), WSWM
0.73 (0.58–0.91), and women who have never had sex 0.02 (0.01–0.02) were less likely to report ever having attended cervical
screening. There were no differences when considering bowel cancer screening uptake (p¼ 0.61). For breast cancer screening,
attendance was lower among WSWM 0.79 (0.68 to 0.91) and women who have never had sex 0.47 (0.29–0.58), compared with
WSEM. There were incident and prevalent cases of both CIN3 and cervical cancer among WSEW and WSWM. Compared
with WSEM with a single male partner, among WSEW there was a twofold increase in CIN3 1.91 (1.01 to 3.59); among WSWM
with only one male partner, this was 2.25 (1.19 to 4.24).
Conclusions: These findings highlight the importance of improving uptake of cervical screening among all women who have
sex with women and breast screening among WSWM and women who have never had sex.
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Introduction
Cervical cancer accounted for 2% of all incident cancer in
women in the UK in 2017 and is the 14th most common
cancer diagnosed; incidence is highest among 30–34 year
olds.1 In 2010–2012, 3.2% of all women and 4.7% of all
25–34-year-old women reported at least one female sexual
partner in the previous five years.2 It is uncertain whether
cervical cancer risk is higher or lower among women who
have sex with women (WSW) because of variation in
human papillomavirus (HPV) and other risk factor prev-
alence, and also disparities in screening history.
HPV is the main cause of cervical cancer. Our previous
research found that HPV-associated cancers were those
where there was greatest variation in risk among sexual
minority women and men; however, we also found that
women who report lesbian or bisexual sexual orientation
were neither over- nor under-represented among women
with cervical cancer.3 A recent systematic review identified
increased risk of cervical cancer among bisexual but not
lesbian women.4 Higher lifetime number of male sexual
partners is a risk factor for HPV infection and cervical
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cancer, and WSW are more likely to have had higher num-
bers of male sexual partners.5,6 Genital HPV transmission
also occurs among women who have sex exclusively with
women (WSEW).7,8 Sexual minority women are likely to
be younger, from more socially deprived backgrounds,
and to smoke, compared with heterosexual women, all of
which are also risk factors for cervical cancer.2,6,9–12
Modelling studies have shown that cervical screening in
the UK has been effective in reducing cervical cancer,13–15
and ensuring equitable access to and uptake of screening
among lesbian and bisexual women is a policy priority in
the UK.16–18 Research from the UK and the US has found
no difference in,19 or lower,8,20,21 cervical screening uptake
among sexual minority women. However, there is little
large-scale population-based data on screening uptake
for any of the UK cancer screening programmes: breast,
bowel (colorectal) or cervical.17 There have been calls from
both the UK and the US to improve data on cancer out-
comes in sexual minority women and men.22,23 A key chal-
lenge is that there are limited population-based or research
databases or cohort studies where sexual orientation is
prospectively recorded.24 UK Biobank is a prospective
cohort study of healthy volunteers from the UK. History
of sex with both same and opposite sex partners was asked
at recruitment, and this cohort is emerging as an important
resource for sexual minority health research.
Cervical screening programmes aim to detect cervical
intraepithelial neoplasia (CIN), a treatable precursor to
cervical cancer. There are three grades of CIN, of which
CIN2 and CIN3 are treated when detected either through
screening or symptomatic presentation. CIN3 diagnoses
are recorded by cancer registries in the UK, and these
data have also been linked to the UK Biobank cohort.25
In this analysis of data from UK Biobank, we describe
screening attendance, and incident and prevalent CIN3
and cervical cancer, among WSW and women who have
sex with men (WSM) in order to answer the following
questions:
Is participation in screening for cervical cancer lower
among WSW compared with women who have sex exclu-
sively with men (WSEM), and is this reflected in lower
cancer screening rates for other cancers as well? Is there




UK Biobank is a large cohort study of healthy volunteers
from the UK recruited at age 37–70 between 2006 and
2010.26,27 A total of 9.2 million postal invitations were
sent to people living within 25 miles of the 22 study assess-
ment centres, and 503,325 people consented and were
recruited, including 273,349 women. Touchscreen com-
puters were used to collect survey questionnaire responses.
The data used in this study were accessed through UK
Biobank (application number 42,861).
Screening history
Questions about screening history were asked to cohort
members of all ages. For cervical screening, cohort mem-
bers were asked “Have you ever had a cervical smear test?”
with response options “Yes”, “No”, “Do not know” and
“Prefer not to answer”. A second question asked "How
many years ago was your last cervical smear test?" with
numerical responses possible, and three additional options
“Less than a year ago”, “Do not know” and “Prefer not to
answer”.
For bowel screening, cohort members were asked
“Have you ever had a screening test for bowel (colorectal)
cancer? (Please include tests for blood in the stool/faeces
or a colonoscopy or a sigmoidoscopy)” with response
options “Yes”, “No”, “Do not know” and “Prefer not to
answer”.
For breast screening, the question was “Have you ever
been for breast cancer screening (a mammogram)?” again
with response options “Yes”, “No”, “Do not know” and
“Prefer not to answer”.
CIN and cervical cancer diagnoses
CIN3 was defined as a cancer registry recorded ICD10
diagnosis code of “D06” or an ICD9 cancer registry
code of 2331. Cervical cancer diagnoses were defined
with an ICD10 code of “C53” or an ICD9 code of
180,018,011,808 or 1809.
We included prevalent cases of CIN3 and cervical
cancer at baseline assessment defined as any cancer regis-
try recorded diagnosis with a first date of diagnosis before
the baseline assessment date.
Incident CIN3 and cervical cancer diagnoses were esti-
mated for the first five years of follow-up after baseline
assessment, as all cohort members had at least five years
of complete follow-up after this date. People with preva-
lent CIN3 or cervical cancer before baseline assessment
were excluded from these analyses of incident cancer.
Sexual history
We identified women who had never had sex, WSEW,
WSEM and WSWM based on responses to sexual history
questions about lifetime numbers of same sex and opposite
sex partners (details in Appendix Figure 1, see online
Supplemental Material).
Cohort characteristics
We described age, ethnicity and smoking history based on
responses to the baseline touchscreen survey. Socio-
economic deprivation was calculated using the Townsend
score, a small area measure of material deprivation based
on postcode of residence. We categorised deprivation into
five groups based on national quintile defining cutpoints;28
people living in the most deprived areas of the UK are
under-represented in UK Biobank.26 We also describe
the recruitment year to UK Biobank because the UK
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bowel screening programme was rolled out between 2006
and 2010,29 and so for bowel screening there will have been
variable uptake across the study period.
Analysis
After excluding missing data (Appendix Table 1) in our
first analysis, we described the characteristics and cervical
cancer risk factor profiles. Because of the differences in the
age profiles of women in these four groups, we estimated
further descriptive statistics stratified by age.
To compare participation in screening for cervical
cancer among WSW compared with WSEM and compare
the patterns of participation with those for bowel and
breast cancer screening, in our second analysis, we com-
pared uptake of cervical, bowel and breast cancer screen-
ing in each group of women. For cervical cancer
screening, we included all women reporting a history of
ever having attended screening and additionally described
up-to-date screening history (under 50 and screened in
the last three years or 50–64 and screened within the
last five years). We restricted the analysis to women
over 50 for breast screening and women over 60 for
bowel screening in line with screening programme ages.
We explored screening uptake in adjusted analysis using
logistic regression, adjusting for age, year of baseline
assessment, deprivation and ethnicity.
In order to explore higher or lower CIN3 or cervical
cancer risk among WSEW, WSWM and WSEM, we
described unadjusted variation in prevalent and incident
CIN3 and cervical cancer among women in each group. In
adjusted analysis, using logistic regression, we only
explored prevalent CIN3 because of small numbers of out-
comes among WSW for prevalent cervical cancer or inci-
dent CIN3 or cervical cancer. In this adjusted analysis,
considering history of CIN3 at baseline assessment, we
described variation between women with no history of
sex with women or men, WSEW, WSEM and WSWM
adjusted for age, deprivation and smoking history.
Because these four groups of women were defined on the
basis of lifetime sexual history, numbers of sexual partners
could not be incorporated into these models. In order to
describe the relationship between lifetime numbers of male
sexual partners and CIN3, we stratified the cohort by his-
tory of ever having sex with women, and in this analysis
explored the relationship with lifetime numbers of male
sexual partners separately in the two groups (women
who reported ever, or never, having had sex with a
woman). We could not stratify by lifetime numbers of
female partners alone because of low numbers in these
groups.
All data processing and analyses were carried out using
Stata 15.1.
Results
After excluding women for whom sexual history (50,531,
22.7%), socio-demographic information (1,591, 0.7%) or
screening history (2,553, 1.2%) was missing, we included
218,674 women in this analysis.
One per cent of women (2192) reported no history of
sex with either women or men, 0.3% (684) sex exclusively
with women (WSEW), 210,866 (96.4%) sex exclusively
with men (WSEM) and 4932 (2.3%) sex with both men
and women (WSWM) (Table 1).
WSEW and WSEM reported similar lifetime numbers
of sexual partners, with 29.5% and 23.2% reporting six or
more; 72.3% of WSWM reported six or more lifetime
partners. WSWM reported fewer female sexual partners
than WSEW and more male sexual partners than WSEM.
Overall, 39.0% of WSEM, 24.0% of women with no
history of sex, 26.9% WSEW and 21.4% WSWM lived
in the least deprived 20% of areas of the UK, and smoking
history was highest among WSEW and WSWM (Table 1).
Lifetime numbers of all and same sex partners were higher
among younger women, although fewer women at older
ages had never had sex with women or men. CIN3 history
was higher among younger women, at 3.6% in under
45 year olds compared with 0.9% in over 65 year olds.
Cohort characteristics are presented in Appendix Tables
2 and 3 (see online Supplemental Material).
Participation in screening
We found that 45.7% of women with no history of sex
with either women or men reported never having attended
cervical cancer screening, and 22.0% of under 50 year olds
and 27.2% of 50 and over year olds in this group reported
up-to-date screening history.
Compared with 1.3% of WSEM and 1.6% of WSWM,
10.5% of WSEW had never attended cervical screening
(Table 2). Overall, a history of ever having attended cer-
vical screening was slightly higher among younger than
older women (Appendix Table 3).
Considering all screening history, in adjusted analysis
[Odds ratio (OR) (95% confidence interval, CI)], WSEM
were the most likely group to have ever had cervical
screening (joint p-value <0.0001), and WSEW were 10
times less likely to have ever attended 0.10 (0.08 to 0.13).
No difference was seen for ever having had bowel screen-
ing (p¼ 0.61), and for breast cancer screening, uptake was
lower among WSWM 0.79 (0.86–0.91) and women who
had never had sex 0.47 (0.29 to 0.58), Table 3. In further
analysis, where we considered only women with an up-to-
date cervical screening history, differences between WSEW
and WSWM compared with WSEM attenuated somewhat
(Table 3).
Incident and prevalent CIN3 and cervical cancer
There were 4386 women (2.0%) in the cohort who had a
history of CIN3 at baseline assessment (prevalent CIN3)
and 196 (0.1%) reports of CIN3 during the first five years
of follow-up (incident CIN3). Overall, 731 (0.3%) women
had a history of cervical cancer at baseline assessment with
46 incident cases during the first five years of follow-up;
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231 cases (31.9%) of cervical cancer occurred among
people with no history of CIN3. Women with all reported
sexual histories (no sexual history, WSEW, WSEM and
WSWM) were represented among both CIN and cervical
cancer cases (Table 4).
In multivariable analysis, women who had never had
sex had a greater than 10-fold lower risk of a history of
CIN3 compared with WSEM. Overall, after adjusting
for age, deprivation and smoking history, WSEW and
WSWM had lower odds of a recorded CIN3 history


















2192 684 210,866 4932
Age at baseline assessment
Under 45 270 (12.3) 155 (22.7) 21,550 (10.2) 1090 (22.1)
45–49 335 (15.3) 175 (25.6) 28,681 (13.6) 1157 (23.5)
50–54 348 (15.9) 124 (18.1) 33,777 (16.0) 1019 (20.7)
55–59 372 (17.0) 89 (13.0) 39,829 (18.9) 815 (16.5)
60–64 484 (22.1) 89 (13.0) 51,370 (24.4) 624 (12.7)
65 and over 383 (17.5) 52 (7.6) 35,659 (16.9) 227 (4.6)
Lifetime number of sexual partners
0 2192 (100)
1 177 (25.9) 71,329 (33.8)
2 to 3 171 (25.0) 55,324 (26.2) 609 (12.3)
4 to 5 134 (19.6) 35,251 (16.7) 755 (15.3)
6 or more 202 (29.5) 48,962 (23.2) 3568 (72.3)
Lifetime number of same sex partners
0 2192 (100) 210,866 (100)
1 177 (25.9) 2480 (50.3)
2 to 3 171 (25.0) 1456 (29.5)
4 to 5 134 (19.6) 485 (9.8)
6 or more 202 (29.5) 511 (10.4)
Lifetime number of opposite sex partners
0 2192 (100) 684 (100)
1 71,329 (33.8) 600 (12.2)
2 to 3 55,324 (26.2) 921 (18.7)
4 to 5 35,251 (16.7) 710 (14.4)
6 or more 48,962 (23.2) 2701 (54.8)
Deprivation
Least deprived 525 (24.0) 184 (26.9) 82,236 (39.0) 1055 (21.4)
2 422 (19.3) 139 (20.3) 45,259 (21.5) 786 (15.9)
3 413 (18.8) 113 (16.5) 31,233 (14.8) 894 (18.1)
4 373 (17) 105 (15.4) 27,018 (12.8) 1024 (20.8)
Most deprived 459 (20.9) 143 (20.9) 25,120 (11.9) 1173 (23.8)
Ethnicity
White 2103 (95.9) 628 (91.8) 202,580 (96.1) 4702 (95.3)
Mixed 10 (0.5) 8 (1.2) 1006 (0.5) 72 (1.5)
Asian 33 (1.5) 17 (2.5) 2431 (1.2) 21 (0.4)
Black 24 (1.1) 12 (1.8) 2773 (1.3) 81 (1.6)
Other 22 (1.0) 19 (2.8) 2076 (1.0) 56 (1.1)
Smoking history
Never 1898 (86.6) 375 (54.8) 127,883 (60.6) 1832 (37.1)
Former 225 (10.3) 211 (30.8) 65,607 (31.1) 2167 (43.9)
Current 69 (3.1) 98 (14.3) 17,376 (8.2) 933 (18.9)
Year of baseline assessment
2006 24 (1.1) 5 (0.7) 1599 (0.8) 40 (0.8)
2007 339 (15.5) 83 (12.1) 20,737 (9.8) 527 (10.7)
2008 794 (36.2) 248 (36.3) 79,628 (37.8) 1644 (33.3)
2009 645 (29.4) 218 (31.9) 72,635 (34.4) 1730 (35.1)
2010 390 (17.8) 130 (19.0) 36,267 (17.2) 991 (20.1)
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compared with WSEM, although the 95%CI cross 1
(Table 5). WSW with a history of no male partners or
only one male partner had a twofold increase in CIN3
compared with WSEM with a history of only one male
partner; OR (95%CI) 1.91 (1.01 to 3.59) for WSW with
a history of no male partners, and 2.25 (1.19 to 4.24) for
WSW with only one male partner (Table 5).
Discussion
WSEW, WSWM and women who have never had sex are
less likely than WSEM to report ever having attended cer-
vical screening. There was no difference between the four
groups when considering bowel cancer screening uptake.
For breast screening, WSWM and women who have never
had sex report lower screening uptake compared with
WSEM. In linked cancer registry data from UK
Biobank, there were incident and prevalent cases of both
CIN3 and cervical cancer among WSEW and WSWM. In
addition, WSEW were more likely to have a history of
CIN3 than women who reported never having sex or
than WSEM with only one sexual partner.
Our finding that lower uptake among WSEW is seen for
cervical screening, but not for bowel or breast, suggests
that it is likely to be due to issues specific to the cervical
cancer screening process. This may relate to historic



















Never screened 1001 (45.7) 72 (10.5) 2806 (1.3) 78 (1.6)
Ever screened 1191 (54.3) 612 (89.5) 208,060 (98.7) 4854 (98.4)
Cervical screening within the last three years (under 50)
No 472 (78.0) 127 (38.5) 7760 (15.5) 407 (18.1)
Yes 133 (22.0) 203 (61.5) 42,471 (84.6) 1840 (81.9)
Cervical screening within the last five years (50–64)
No 877 (72.8) 100 (33.1) 31,488 (25.2) 592 (24.1)
Yes 327 (27.2) 202 (66.9) 93,488 (74.8) 1866 (75.9)
Bowel screening (60þ only)
Never screened 454 (52.4) 71 (50.4) 42,888 (49.3) 411 (48.3)
Ever screened 413 (47.6) 70 (49.6) 44,141 (50.7) 440 (51.7)
Breast screening (50þ only)
Never screened 123 (7.8) 29 (8.2) 6273 (3.9) 218 (8.1)
Ever screened 1464 (92.2) 325 (91.8) 154,362 (96.1) 2467 (91.9)
Table 3. Predictors of screening attendance.
OR (95%CI) p-value OR (95%CI) p-value
Cervical screening (ever) Cervical screening (up to date at
baseline assessment, under 65 only)
No history of sex with either women or men 0.02 (0.01 to 0.02) <0.0001 0.09 (0.08 to 0.1) <0.0001
Sex exclusively with women (WSEW) 0.10 (0.08 to 0.13) 0.42 (0.35 to 0.49)
Sex exclusively with men (WSEM) Reference Reference
Sex with both women and men (WSWM) 0.73 (0.58 to 0.91) 0.91 (0.84 to 0.97)
Bowel screening (over 60 only)
No history of sex with either women or men 0.96 (0.83 to 1.11) 0.61
Sex exclusively with women (WSEW) 0.87 (0.61 to 1.24)
Sex exclusively with men (WSEM) Reference
Sex with both women and men (WSWM) 0.93 (0.81 to 1.08)
Breast screening (over 50 only)
No history of sex with either women or men 0.47 (0.39 to 0.58) <0.0001
Sex exclusively with women (WSEW) 0.70 (0.47 to 1.05)
Sex exclusively with men (WSEM) Reference
Sex with both women and men (WSWM) 0.79 (0.68 to 0.91)
Note: Adjusted for age, ethnicity, year of baseline assessment, and deprivation.
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messaging which specifically discouraged cervical screen-
ing among lesbian and bisexual women in the UK21 (it was
only in 2009 that the UK government began to proactively
promote cervical screening uptake among lesbian and
bisexual women30) or because opportunities for cervical
screening are missed if they are routinely carried out
during contraceptive review appointments, which lesbian
and bisexual women may be less likely to attend.31 The
Table 4. Incident and prevalent CIN3 and cervical cancer.
All women













No 214,288 (98.0) 2189 (99.9) 674 (98.5) 206,626 (98) 4799 (97.3)




follow up (n¼ 214,288)a
No 214,092 (99.0) 2189 (100) 674 (100) 206,434 (99.9) 4795 (99.9)




No 217,943 (99.7) 2190 (99.9) 683 (99.9) 210,156 (99.7) 4914 (99.6)
Yes 731 (0.3) 2 (0.1) 1 (0.1) 710 (0.3) 18 (0.4)
Incident cervical
cancer within
5 years of follow
up (n¼ 217,943)a
No 217,897 (100.0) 2189 (100) 683 (100) 210,112 (100) 4913 (100)
Yes 46 (0.0) 1 (0) 0 (0) 44 (0) 1 (0)
aThe denominator for incident CIN3/cervical cancer excludes prevalent cases at baseline.
Table 5. Association between same and opposite sex sexual history and history of CIN3 at UK Biobank baseline assessment.







OR (95%CI) OR (95%CI) OR (95%CI)
No history of sex with either women or men 0.07 (0.02 to 0.21) 0.06 (0.02 to 0.19) 0.08 (0.02 to 0.24)
Sex exclusively with women (WSEW) 0.72 (0.39 to 1.35) 0.56 (0.30 to 1.06) 0.53 (0.28 to 1.00)
Sex exclusively with men (WSEM) Reference Reference Reference
Sex with both women and men (WSWM) 1.35 (1.13 to 1.61) 1.02 (0.85 to 1.21) 0.86 (0.72 to 1.03)
joint p-value <0.0001 <0.0001 <0.0001
Model 2. Including lifetime numbers of male sexual partners, adjusted for age, deprivation, smoking history
No history of sex with women (women who have never had sex and WSEM) Women who have sex
with women (WSEW and WSWM)
Lifetime number of male sexual partners OR (95%CI) Lifetime number of
male sexual partners
OR (95%CI)
0 0.23 (0.07 to 0.72) 0 1.91 (1.01 to 3.59)
1 reference 1 2.25 (1.19 to 4.24)
2 to 3 2.70 (2.39 to 3.04) 2 to 3 2.50 (1.55 to 4.04)
4 to 5 4.05 (3.59 to 4.57) 4 to 5 1.90 (1.04 to 3.48)
6 or more 5.37 (4.79 to 6.02) 6 or more 3.98 (3.15 to 5.03)
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practice of refusing contraception prescriptions unless cer-
vical screening is completed may exacerbate these differ-
ences.32 Dislike of, or pain associated with, the use of a
speculum during cervical screening may be a further
reason for lower screening uptake among some WSEW,
although most lesbian and bisexual women report vaginal
penetration occasionally or often with female or male
sexual partners.33
Challenges in accessing healthcare among lesbian, gay
and bisexual women,34 or generally poorer experiences of
primary or cancer care,11,35,36 remain important issues for
the health of sexual minority women. As cervical screening
is the only one of the three UK screening programmes
carried out in primary care, these may be additional pos-
sible explanations for the specifically lower attendance for
cervical screening.
Our findings that WSEW and WSWM are represented
among women with a history of CIN3 or cervical cancer
highlight the ongoing importance of screening among these
groups. Although, on average, WSEW are about half as
likely to have a history of CIN3 than WSEM, we find no
statistical evidence of reduced risk when compared with all
WSEM (95% confidence intervals include 1). This lower
risk should therefore not be over-interpreted, however cau-
tiously it may be explained by either lower screening atten-
dance or lower risk of CIN3 associated with sex exclusively
with women or a combination of both. Our finding that
WSEW have a higher prevalence of CIN3 when compared
only with women who have had a single male partner is an
important indication that lesbian compared with heterosex-
ual sex alone cannot be the only explanation for this lower
risk, again highlighting the importance of screening among
these groups. We additionally find no evidence to support
the possibility that higher cervical cancer risk among lesbian
and bisexual women is explained by higher numbers of male
sexual partners in these groups.4
Cervical cancer screening is associated with a 60% reduc-
tion in cancer in women aged 40 and 80% at age 64.14 Three
per cent of women treated for CIN3 would have had cancer
by age 40 had the CIN3 not been treated.13 Interventions to
encourage uptake of screening among sexual minority
women should be particularly targeted at cervical cancer,
and our analysis suggests that the current policy focus is
warranted.16,17 Women who have never had sex are less
likely to have ever had cervical screening, but given the
known aetiology associated with HPV infection, cervical
cancer risk is also likely to be substantially lower in this
group; there is a less strong argument for targeting cervical
screening among these women. However, our finding that
mammography uptake is also lower, despite evidence of
higher breast cancer risk associated with nulliparity,37 sug-
gests this is a group to whom breast cancer screening uptake
interventions could potentially be targeted. This analysis
also highlights the importance of the collection or linkage
of sexual orientation and sexual behaviour information for
UK cancer registries to allow disparities in cancer outcomes
to be monitored and reported.
The key strengths of this analysis are the large sample
size and the cancer registry linked cancer outcomes data,
combined with self-reported screening information and
sexual history for women in the UK Biobank cohort.
Public Health England have highlighted the lack of data
available on screening uptake among the lesbian, gay,
bisexual, transgender population,17 and this analysis goes
part of the way towards addressing this evidential need.
There are limitations to this analysis. UK Biobank is
not representative of the UK population26 and, specifically
relevant to this analysis, our finding that cervical screening
history is higher among younger compared with older
women varies from the pattern seen in the UK as a
whole.38 This is the strongest limitation to this work; to
address this concern, we adjusted for age, deprivation and
ethnicity in multivariable analysis. A second limitation is
that we explored sexual history rather than sexual orien-
tation, and although this may be appropriate for analyses
exploring disparities in cancer outcomes associated with
sexually transmitted HPV infection,3 it should be
highlighted that most WSWM identify as heterosexual
rather than bisexual or lesbian,39 and so caution is
needed before using these results to describe disparities
associated with sexual identity.
A third limitation is that we could not specifically
explore screening uptake associated with national bowel
and breast screening programmes because the measure of
screening in UK Biobank could incorporate both diagnos-
tic testing and asymptomatic screening. In this analysis,
screening for cervical cancer is different from bowel and
breast in the context of the questions asked; for bowel and
breast screening, the investigations could be being done
following symptomatic presentation, but cervical cancer
smear tests cannot be carried out in primary care outside
the context of the national screening programme.
Regarding CIN3 and cancer outcomes, there is the
potential for survivor bias in this analysis, although the
low mortality overall from CIN3 will mitigate this some-
what. Further, for analyses of CIN3, we were not able to
adjust for screening history, as almost everyone with a
history of CIN3 reported having attended screening at
least once in their lifetime. We include incident and prev-
alent cervical cancer in this analysis in descriptive statis-
tics, as these diagnoses represent cases of cancer not
prevented by screening, although numbers were not high
enough for a multivariable analysis.
Age, screening history, sexual history and CIN3 risk are
all related. In addition to cohort effects in screening pro-
gramme roll-out, it is possible also that completeness of
cancer recording varies over time. The descriptive age and
socio-demographic stratified supplementary analyses shed
some more light on these relationships.
Despite these limitations, this analysis presents novel
findings from a large cohort of women in the UK. For
cervical screening, we find lower uptake among WSW
(both WSEW and WSWM), a finding that is not mirrored
in bowel screening uptake. We also show that WSEW and
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WSWM are represented among all women with CIN3 and
cervical cancer diagnoses, and that WSEW have higher
CIN3 prevalence than women who have had one or zero
male partners across their lifetimes, confirming the risk of
HPV transmission associated with lesbian sex. Together,
these findings highlight the importance of policy interven-
tions to improve uptake of cervical screening among
women who have sex with women overall.
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